Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) EBIT Margin (2021 - 2025)

Historic EBIT Margin for Krystal Biotech (KRYS) over the last 4 years, with Q4 2025 value amounting to 41.33%.

  • Krystal Biotech's EBIT Margin fell 40800.0% to 41.33% in Q4 2025 from the same period last year, while for Dec 2025 it was 41.41%, marking a year-over-year increase of 187800.0%. This contributed to the annual value of 41.45% for FY2025, which is 188200.0% up from last year.
  • Latest data reveals that Krystal Biotech reported EBIT Margin of 41.33% as of Q4 2025, which was down 40800.0% from 42.3% recorded in Q3 2025.
  • Krystal Biotech's EBIT Margin's 5-year high stood at 962.0% during Q1 2021, with a 5-year trough of 303.8% in Q3 2023.
  • Moreover, its 4-year median value for EBIT Margin was 40.93% (2025), whereas its average is 81.92%.
  • In the last 5 years, Krystal Biotech's EBIT Margin soared by 3306000bps in 2024 and then plummeted by -40800bps in 2025.
  • Quarter analysis of 4 years shows Krystal Biotech's EBIT Margin stood at 962.0% in 2021, then crashed by -99bps to 7.71% in 2023, then skyrocketed by 489bps to 45.41% in 2024, then decreased by -9bps to 41.33% in 2025.
  • Its last three reported values are 41.33% in Q4 2025, 42.3% for Q3 2025, and 40.93% during Q2 2025.